<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02414165</url>
  </required_header>
  <id_info>
    <org_study_id>Tg 511-15-01</org_study_id>
    <secondary_id>FD-R-5732</secondary_id>
    <nct_id>NCT02414165</nct_id>
  </id_info>
  <brief_title>The Toca 5 Trial: Toca 511 &amp; Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma</brief_title>
  <acronym>Toca5</acronym>
  <official_title>A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tocagen Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tocagen Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, randomized, open-label phase 2/3 study of Toca 511 and Toca FC versus&#xD;
      standard of care that comprises Investigator's choice of single agent chemotherapy (lomustine&#xD;
      or temozolomide) or bevacizumab administered to subjects undergoing resection for first or&#xD;
      second recurrence (including this recurrence) of GBM or AA. Subjects meeting all of the&#xD;
      inclusion and none of the exclusion criteria will be randomized prior to surgery in a 1:1&#xD;
      ratio to receive either Toca 511 and Toca FC (Experimental arm, Arm T) or control treatment&#xD;
      with one option of standard of care (Arm SOC). Stratification will be done by IDH1 mutation&#xD;
      status. A second stratification factor is based on the patient's Karnofsky Performance Score&#xD;
      (KPS) (70-80 vs 90-100). Further, to account for potential differences in treatment choices&#xD;
      for the control arm in regions, the trial will be stratified by geographical region during&#xD;
      the randomization process.&#xD;
&#xD;
      Funding Source - FDA OOPD&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Sponsor Decision&#xD;
  </why_stopped>
  <start_date type="Actual">November 30, 2015</start_date>
  <completion_date type="Actual">December 20, 2019</completion_date>
  <primary_completion_date type="Actual">May 31, 2019</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To compare the overall survival (OS) of subjects treated with Toca 511 combined with Toca FC to subjects treated according to standard of care after tumor resection for recurrence of glioblastoma or anaplastic astrocytoma</measure>
    <time_frame>30 December 2019</time_frame>
    <description>Time from randomization date to death due to any cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Durable Response Rate (CR or PR ≥ 24 weeks)</measure>
    <time_frame>30 December 2019</time_frame>
    <description>The proportion of patients whose best response is either CR or PR lasting at least 24 weeks, according to modified RANO criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Durable Clinical Benefit Rate (CR or PR ≥ 24 weeks or SD ≥ 18 months)</measure>
    <time_frame>30 December 2019</time_frame>
    <description>The proportion of subjects whose best overall response is either CR or PR lasting at least 24 weeks, or stable disease (SD) lasting at least 18 months, according to modified RANO criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Durable Response</measure>
    <time_frame>30 December 2019</time_frame>
    <description>Time from documentation of durable response to disease progression or death due to disease progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival at 12 months</measure>
    <time_frame>30 December 2019</time_frame>
    <description>Time from randomization date to death due to any cause</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">403</enrollment>
  <condition>Glioblastoma Multiforme</condition>
  <condition>Anaplastic Astrocytoma</condition>
  <arm_group>
    <arm_group_label>Toca 511/Toca FC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Resection followed by administration of 4 mL Toca 511 (vocimagene amiretrorepvec). Toca 511 is administered by injection into the wall of the subject's tumor resection cavity on Day 1 (approximately 40 injections of 0.1 mL)&#xD;
Toca FC is an extended-release formulation of flucytosine. Toca FC will be administered at 220 mg/kg/day orally for 7-day courses beginning at least 6 weeks after resection and repeated approximately every 6 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lomustine, Temozolomide, or Bevacizumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Investigator selects one of the following:&#xD;
Bevacizumab: Beginning 6 weeks after tumor resection, bevacizumab will be administered by IV infusion at 10 mg/kg and repeated every 2 weeks. Refer to the prescribing information and to institutional guidelines for details on the administration procedure.&#xD;
Lomustine: Beginning 6 weeks after tumor resection, lomustine will be administered as a single oral dose of 110 mg/m2 and repeated every 6 weeks. Refer to the prescribing information and to institutional guidelines for details regarding the administration procedure.&#xD;
Temozolomide: Beginning 6 weeks after tumor resection, temozolomide will be administered per 1 of 2 options:&#xD;
at a dose of 50 mg/m2 PO once daily continuously, or&#xD;
at an initial dose of 150 mg/m2 IV or PO once daily for 5 consecutive days per 28-day treatment cycle that may be raised to 200 mg/ m2 once daily for 5 consecutive days in the following 28-day treatment cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Toca 511</intervention_name>
    <description>Toca 511 consists of a purified retroviral replicating vector encoding a modified yeast cytosine deaminase (CD) gene. The CD gene converts the antifungal 5-flurocytosine (5FC) to the anticancer drug 5-FU in cells that have been infected by the Toca 511 vector.</description>
    <arm_group_label>Toca 511/Toca FC</arm_group_label>
    <other_name>vocimagene amiretrorepvec</other_name>
    <other_name>RRV</other_name>
    <other_name>retroviral replicating vector</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Toca FC</intervention_name>
    <description>Toca FC is an extended-release formulation of flucytosine and is supplied as 500 mg tablets</description>
    <arm_group_label>Toca 511/Toca FC</arm_group_label>
    <other_name>flucytosine</other_name>
    <other_name>5-FC</other_name>
    <other_name>5-fluorocytosine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lomustine</intervention_name>
    <arm_group_label>Lomustine, Temozolomide, or Bevacizumab</arm_group_label>
    <other_name>CCNU</other_name>
    <other_name>CeeNU</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide</intervention_name>
    <arm_group_label>Lomustine, Temozolomide, or Bevacizumab</arm_group_label>
    <other_name>Temodar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <arm_group_label>Lomustine, Temozolomide, or Bevacizumab</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject has given written informed consent&#xD;
&#xD;
          2. Subject is between 18 years old and 75 years old, inclusive&#xD;
&#xD;
          3. Subjects must have histologically proven GBM or AA and:&#xD;
&#xD;
               1. Must have received first-line multimodal therapy with surgery followed by&#xD;
                  temozolomide (unless MGMT promoter unmethylated) and radiation (subjects with GBM&#xD;
                  must have received temozolomide and radiation concurrently)&#xD;
&#xD;
               2. Must be in first or second recurrence (including this recurrence)&#xD;
&#xD;
               3. Recurrence must be confirmed by diagnostic biopsy with local pathology review or&#xD;
                  contrast-enhanced MRI. If first recurrence of GBM is documented by MRI, an&#xD;
                  interval of at least 12 weeks after the end of prior radiation therapy is&#xD;
                  required unless there is either: i) histopathologic confirmation of recurrent&#xD;
                  tumor, or ii) new enhancement on MRI outside of the radiotherapy treatment field&#xD;
&#xD;
          4. Subjects must have measurable disease preoperatively, defined as at least 1&#xD;
             contrast-enhancing lesion, with 2 perpendicular measurements of at least 1 cm, as per&#xD;
             RANO criteria&#xD;
&#xD;
          5. Subjects must be at least 4 weeks post last dose of temozolomide&#xD;
&#xD;
          6. Prior gamma knife, stereotactic radiosurgery, or other focal high-dose radiotherapy is&#xD;
             allowed but the subject must have either histopathologic confirmation of recurrent&#xD;
             tumor, or new enhancement on MRI outside of the radiotherapy treatment field&#xD;
&#xD;
          7. Based on the pre-operative evaluation by neurosurgeon, the subject is a candidate for&#xD;
             ≥ 80% resection of enhancing region&#xD;
&#xD;
          8. IDH mutation status of the primary tumor must be available or tumor samples must be&#xD;
             available for pre randomization testing&#xD;
&#xD;
          9. Laboratory values adequate for patient to undergo surgery, including:&#xD;
&#xD;
               -  Platelet count ≥ 60,000/mm3&#xD;
&#xD;
               -  Hgb ≥ 10 g/dL&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) ≥ 1,500/mm3&#xD;
&#xD;
               -  Absolute lymphocyte count (ALC) ≥ 500/mm3&#xD;
&#xD;
               -  Adequate liver function, including:&#xD;
&#xD;
                    -  Total bilirubin ≤ 1.5 x ULN (unless has Gilbert's syndrome)&#xD;
&#xD;
                    -  ALT ≤ 2.5 x ULN f. Estimated glomerular filtration rate of at least 50&#xD;
                       mL/min by the Cockcroft Gault formula&#xD;
&#xD;
         10. Women of childbearing potential (≥12 months of non-therapy-induced amenorrhea or&#xD;
             surgically sterile) must have had a negative serum pregnancy test within the past 21&#xD;
             days and must use a birth control method in addition to barrier methods (condoms).&#xD;
&#xD;
         11. Subject or subject's partner is willing to use condoms for 12 months after receiving&#xD;
             Toca 511 or until there is no evidence of the virus in his/her blood, whichever is&#xD;
             longer.&#xD;
&#xD;
         12. The subject has a KPS ≥ 70&#xD;
&#xD;
         13. The subject is willing and able to abide by the protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of more than 2 prior recurrences (including this recurrence) of GBM or AA&#xD;
&#xD;
          2. History of other malignancy, unless the patient has been disease free for at least 5&#xD;
             years. Adequately treated basal cell carcinoma or squamous cell skin cancer is&#xD;
             acceptable regardless of time, as well as localized prostate carcinoma or cervical&#xD;
             carcinoma in situ after curative treatment&#xD;
&#xD;
          3. Histologically confirmed oligodendroglioma or mixed glioma&#xD;
&#xD;
          4. Known 1p/19q co deletion&#xD;
&#xD;
          5. A contrast enhancing brain tumor that is any of the following:&#xD;
&#xD;
               -  Multi focal (defined as 2 separate areas of contrast enhancement measuring at&#xD;
                  least 1 cm in 2 planes that are not contiguous on either fluid attenuated&#xD;
                  inversion recovery (FLAIR) or T2 sequences);&#xD;
&#xD;
               -  Associated with either diffuse subependymal or leptomeningeal dissemination; or&#xD;
&#xD;
               -  &gt; 5 cm in any dimension&#xD;
&#xD;
          6. The subject has or had any active infection requiring systemic antibiotic, antifungal&#xD;
             or antiviral therapy within the past 4 weeks&#xD;
&#xD;
          7. The subject has any bleeding diathesis, or must take anticoagulants, or antiplatelet&#xD;
             agents, including nonsteroidal anti inflammatory drugs (NSAIDs), at the time of the&#xD;
             scheduled resection that cannot be stopped for surgery&#xD;
&#xD;
          8. The subject is human immunodeficiency virus (HIV) positive&#xD;
&#xD;
          9. The subject has a history of allergy or intolerance to flucytosine&#xD;
&#xD;
         10. The subject has a gastrointestinal disease that would prevent him or her from being&#xD;
             able to swallow or absorb flucytosine&#xD;
&#xD;
         11. The subject received cytotoxic chemotherapy within the past 4 weeks (6 weeks for&#xD;
             nitrosoureas) of the planned surgery date&#xD;
&#xD;
         12. The subject received any investigational treatment within the past 30 days or prior&#xD;
             immunotherapy or antibody therapy within the past 45 days.&#xD;
&#xD;
         13. The subject is pregnant or breast feeding&#xD;
&#xD;
         14. The subject intends to undergo treatment with the Gliadel® wafer at the time of this&#xD;
             surgery or has received the Gliadel® wafer &lt; 30 days from W1D1 (surgery)&#xD;
&#xD;
         15. The subject has received bevacizumab for their disease unless in the context of&#xD;
             primary therapy for newly diagnosed glioma&#xD;
&#xD;
         16. For subjects planned to potentially receive bevacizumab, they have no evidence of&#xD;
             uncontrolled hypertension (defined as a blood pressure of ≥ 150 mm Hg systolic and/or&#xD;
             ≥ 100 mm Hg diastolic on medication) or active GI perforation&#xD;
&#xD;
         17. The subject has received systemic dexamethasone continuously at a dose &gt; 8 mg/day for&#xD;
             8 weeks prior to the date of the screening assessment&#xD;
&#xD;
         18. Severe pulmonary, cardiac or other systemic disease, specifically:&#xD;
&#xD;
               -  New York Heart Association &gt; Grade 2 congestive heart failure within 6 months&#xD;
                  prior to study entry, unless asymptomatic and well controlled with medication&#xD;
&#xD;
               -  Uncontrolled or significant cardiovascular disease, clinically significant&#xD;
                  ventricular arrhythmia (such as ventricular tachycardia, ventricular&#xD;
                  fibrillation, or Torsades des pointes), clinically significant pulmonary disease&#xD;
                  (such as ≥ Grade 2 dyspnea, according to CTCAE 4.03)&#xD;
&#xD;
               -  Subjects who have any other disease, either metabolic or psychological, which as&#xD;
                  per Investigator assessment may affect the subject's compliance or place the&#xD;
                  subject at higher risk of potential treatment complications&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Timothy Cloughesy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Barrow Neurological Institute at Dignity Health St. Joseph's Hospital and Medical Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, Irvine</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California San Diego</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph Hospital</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Cancer Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Colorado Neurological Institute</name>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <zip>80113</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Associated Neurologists of Southern Connecticut</name>
      <address>
        <city>Fairfield</city>
        <state>Connecticut</state>
        <zip>06824</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University/Yale Cancer Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida McKnight Brain Institute</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NorthShore University Health System</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University School of Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abbott Northwestern Hospital / Allina Health</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HCA Midwest / Sarah Cannon</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University St. Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JFK Medical Center Neuroscience Institute</name>
      <address>
        <city>Edison</city>
        <state>New Jersey</state>
        <zip>08820</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Theurer Cancer Center at Hackensack University</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Overlook Medical Center</name>
      <address>
        <city>Summit</city>
        <state>New Jersey</state>
        <zip>07901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Shore University Hospital</name>
      <address>
        <city>Lake Success</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU Langone Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stony Brook University Hospital</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati's Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Cleveland Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanford Research</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor University Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houston Methodist Hospital Outpatient Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center at Houston (UTHealth)</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia Health System</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inova Dwight and Martha Schar Cancer Institute</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sentara Neurosurgery Specialists</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Virginia University</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Alberta</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of British Columbia / Vancouver General Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CancerCare Manitoba</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3E 0V9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Regional Cancer Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5W9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ottawa Hospital Regional Cancer Centre</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Hospital / Sunnybrook Research Institute</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto Western Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 2S8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montreal Neurological Institute</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3A 2B4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jewish General Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sherbrooke Hospital University Centre (CHUS)</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rambam Health Care</name>
      <address>
        <city>Haifa</city>
        <zip>3109601</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hadassah Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tel Aviv Sourasky Medical Center</name>
      <address>
        <city>Tel-Aviv</city>
        <zip>6423906</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul St. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>06591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Israel</country>
    <country>Korea, Republic of</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>April 3, 2015</study_first_submitted>
  <study_first_submitted_qc>April 7, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 10, 2015</study_first_posted>
  <last_update_submitted>February 6, 2020</last_update_submitted>
  <last_update_submitted_qc>February 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Recurrence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Astrocytoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Flucytosine</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Lomustine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

